Incyte Dirección
Dirección controles de criterios 4/4
El CEO de Incyte's es Herve Hoppenot , nombrado en Jan 2014, tiene una permanencia de 10.25 años. compensación anual total es $16.67M, compuesta por 7.4% salario y 92.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.15% de las acciones de la empresa, por valor de $16.89M. La antigüedad media del equipo directivo y de la junta directiva es de 8 años y 7.3 años, respectivamente.
Información clave
Herve Hoppenot
Chief Executive Officer (CEO)
US$16.7m
Compensación total
Porcentaje del salario del CEO | 7.8% |
Permanencia del CEO | 10.3yrs |
Participación del CEO | 0.2% |
Permanencia media de la dirección | 8.3yrs |
Promedio de permanencia en la Junta Directiva | 7.3yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings
May 07Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)
May 03Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Apr 26Incyte: A Potential GARP Superstar
Feb 27Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Feb 02Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Oct 31Knight's affiliate files for Brazilian approval of cancer drug tafasitamab
Oct 07Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart
Sep 29Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia
Sep 15Incyte wins approval of Pemazyre for rare blood cancer
Aug 26Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%
Aug 02With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case
Jul 27Incyte Corp. Should Move Higher (Technical Analysis)
Jul 18Incyte: Growth Drivers Are Coming
Jun 17Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures
Apr 14Incyte: All Atention On Opzelura
Mar 21Incyte: Still Has Room To Grow
Jan 24Incyte: The Right Time To Buy The Stock
Dec 28Análisis de compensación del CEO
Fecha | Compensación total | Salario | Ingresos de la empresa |
---|---|---|---|
Mar 31 2024 | n/a | n/a | US$745m |
Dec 31 2023 | US$17m | US$1m | US$598m |
Sep 30 2023 | n/a | n/a | US$425m |
Jun 30 2023 | n/a | n/a | US$366m |
Mar 31 2023 | n/a | n/a | US$324m |
Dec 31 2022 | US$17m | US$1m | US$341m |
Sep 30 2022 | n/a | n/a | US$876m |
Jun 30 2022 | n/a | n/a | US$945m |
Mar 31 2022 | n/a | n/a | US$933m |
Dec 31 2021 | US$14m | US$1m | US$949m |
Sep 30 2021 | n/a | n/a | US$535m |
Jun 30 2021 | n/a | n/a | US$338m |
Mar 31 2021 | n/a | n/a | US$478m |
Dec 31 2020 | US$16m | US$1m | -US$296m |
Sep 30 2020 | n/a | n/a | -US$335m |
Jun 30 2020 | n/a | n/a | -US$191m |
Mar 31 2020 | n/a | n/a | -US$376m |
Dec 31 2019 | US$15m | US$1m | US$447m |
Sep 30 2019 | n/a | n/a | US$405m |
Jun 30 2019 | n/a | n/a | US$306m |
Mar 31 2019 | n/a | n/a | US$253m |
Dec 31 2018 | US$9m | US$996k | US$109m |
Sep 30 2018 | n/a | n/a | -US$109m |
Jun 30 2018 | n/a | n/a | -US$102m |
Mar 31 2018 | n/a | n/a | -US$167m |
Dec 31 2017 | US$16m | US$967k | -US$313m |
Compensación vs. Mercado: La compensación total ($USD16.67M) de Herve está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD13.51M).
Compensación vs. Ingresos: La compensación de Herve ha sido consistente con los resultados de la empresa en el último año.
CEO
Herve Hoppenot (63 yo)
10.3yrs
Permanencia
US$16,659,526
Compensación
Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...
Equipo directivo
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO & Chairman | 10.3yrs | US$16.66m | 0.15% $ 19.7m | |
President and Head of Research & Development | less than a year | US$16.57m | sin datos | |
Executive VP & CFO | 5.3yrs | US$5.08m | 0.011% $ 1.4m | |
Executive VP & GM of North America | 8.9yrs | US$4.09m | 0.013% $ 1.7m | |
Executive VP & Chief Medical Officer | 9.2yrs | US$5.63m | 0.0011% $ 146.9k | |
VP of Finance | 2.2yrs | sin datos | 0.0035% $ 451.1k | |
Executive VP & Head of Global Technical Operations | 8.3yrs | sin datos | 0.016% $ 2.1m | |
Head of Investor Relations | no data | sin datos | sin datos | |
Executive VP | less than a year | sin datos | sin datos | |
Vice President of Investor Relations & Corporate Communications | no data | sin datos | sin datos | |
Executive Vice President of Human Resources | 21.8yrs | US$1.31m | 0.021% $ 2.7m | |
Executive VP of Global Medical Affairs | no data | US$3.30m | 0.0055% $ 703.7k |
8.3yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de INCY es experimentado (8 años antigüedad media).
Miembros de la Junta
Nombre | Posición | Permanencia | Compensación | Propiedad |
---|---|---|---|---|
CEO & Chairman | 10.3yrs | US$16.66m | 0.15% $ 19.7m | |
Independent Director | 9.3yrs | US$478.76k | 0.0058% $ 745.0k | |
Independent Lead Director | 22.5yrs | US$512.76k | 0.25% $ 32.1m | |
Independent Director | 2.7yrs | US$454.76k | 0.0015% $ 194.6k | |
Independent Director | 7.3yrs | US$466.26k | 0.0051% $ 658.6k | |
Independent Director | 4.4yrs | US$482.26k | 0.0047% $ 609.6k | |
Independent Director | 4.2yrs | US$454.76k | 0.0024% $ 314.5k | |
Independent Director | 9.3yrs | US$479.76k | 0.0059% $ 761.7k | |
Independent Director | 1.6yrs | US$444.76k | 0.00051% $ 65.7k |
7.3yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de INCY se considera experimentada (7.3 años de antigüedad promedio).